Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Gupta, Shaloo [1 ]
Clancy, Zoe [2 ]
Copher, Ronda [2 ]
Rosenberg, Aaron Seth [3 ]
机构：
[1] Kantar, New York, NY USA
[2] Celgene Corp, Summit, NJ USA
[3] Univ Calif Davis, Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA 95817 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Multiple myeloma; Patient Reported Measures; Pomalidomide;
D O I：
10.1016/j.clml.2019.09.443
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-117
引用
收藏
页码：E268 / E269
页数：3
相关论文
共 50 条
  • [1] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
    Dimopoulos, M. A.
    Sonneveld, P.
    Siegel, D.
    Palumbo, A.
    San-Miguel, J.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
  • [2] Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
    Francesco Sparano
    Michele Cavo
    Pasquale Niscola
    Tommaso Caravita
    Fabio Efficace
    Supportive Care in Cancer, 2018, 26 : 2075 - 2090
  • [3] Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
    Sparano, Francesco
    Cavo, Michele
    Niscola, Pasquale
    Caravita, Tommaso
    Efficace, Fabio
    SUPPORTIVE CARE IN CANCER, 2018, 26 (07) : 2075 - 2090
  • [4] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [5] Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone
    Hagiwara, May
    Panjabi, Sumeet
    Sharma, Arati
    Delea, Thomas E.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 818 - 829
  • [6] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [7] The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed/refractory multiple myeloma
    Xu, Jing
    Giesen, Nicola
    Paramasivam, Nagarajan
    Goldschmidt, Hartmut
    Brors, Benedikt
    Raab, Marc S.
    Weinhold, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E83 - E84
  • [8] The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
    Wang, Tzu-Fei
    Ahluwalia, Rohan
    Fiala, Mark A.
    Trinkaus, Kathryn M.
    Cox, Doug P.
    Jaenicke, Matthew
    Moliske, Caitlin C.
    Carson, Kenneth R.
    Wildes, Tanya M.
    Tomasson, Michael H.
    Stockerl-Goldstein, Keith E.
    Vij, Ravi
    LEUKEMIA & LYMPHOMA, 2014, 55 (02) : 337 - 341
  • [9] Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
    Mark, Tomer M.
    Coleman, Morton
    Niesvizky, Ruben
    LEUKEMIA RESEARCH, 2014, 38 (05) : 517 - 524
  • [10] Pomalidomide: A novel imunomodulatory drug for the treatment of relapsed and refractory multiple myeloma
    Bajaj, Nikki
    Shaaban, Hamid
    Maroules, Michael
    Guron, Gunwant
    CLINICAL CANCER INVESTIGATION JOURNAL, 2014, 3 (03): : 200 - 207
12345